Results 231 to 240 of about 1,721,954 (363)

Chromosomes are target sites for photodynamic therapy as demonstrated by subcellular laser microirradiation [PDF]

, 2000
Liang Hong, Tuyen Do, Sanaz Kasravi, Parnaz Aurasteh, Andrea Nguyen, Andy Huang, Zhuotong Wang, Michael W. Berns   +7 more
openalex   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Macrophage membrane-functionalized nanotherapeutics for tumor targeted therapy. [PDF]

Theranostics
Khan M, Ullah R, Wang G, Chu M.
europepmc   +1 more source

Message Therapy: Gene Therapy That Targets mRNA Sequence and Stability

, 1997
Karen Kozarsky, Larry A. Couture
openalex   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Colorectal Cancer: Pathogenesis and Targeted Therapy. [PDF]

MedComm (2020)
Li J, Pan J, Wang L, Ji G, Dang Y.
europepmc   +1 more source

25 Specific intracellular signal transduction pathways downstream of CSF-1 receptors: Their relationship to breast cancer local recurrence and distant relapse in vivo. Potential targets for the development of new, specific anti-breast cancer therapies to improve local control and block metastatic spread?

, 1997
Barry M. Kacinski, Eva Sapi, Maryann B. Flick, Bruce Turner, Peter L. Perrotta, Moataz Maher, Darryl Carter, Bruce G. Haffty   +7 more
openalex   +1 more source

Hypoxia-inducible expression of BAX: application in tumor-targeted gene therapy [PDF]

, 2000
Hangjun Ruan, Lily Hu, Jingli Wang, Tomoko Ozawa, Nader Sanai, Michael Zhang, Kathleen R. Lamborn, Dennis F. Deen   +7 more
openalex   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Targeted therapy for idiopathic pulmonary fibrosis: a bibliometric analysis of 2004-2024. [PDF]

Front Med (Lausanne)
Zhang X, Yuan Z, Shi X, Yang J.
europepmc   +1 more source